0001415889-24-010060.txt : 20240403 0001415889-24-010060.hdr.sgml : 20240403 20240403170044 ACCESSION NUMBER: 0001415889-24-010060 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Walker Neal CENTRAL INDEX KEY: 0001604457 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 24819814 MAIL ADDRESS: STREET 1: 15 NEW ENGLAND EXECUTIVE PARK CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 4 1 form4-04032024_090431.xml X0508 4 2024-04-01 0001557746 Aclaris Therapeutics, Inc. ACRS 0001604457 Walker Neal C/O ACLARIS THERAPEUTICS, INC. 701 LEE ROAD, SUITE 103 WAYNE PA 19087 true true false false INTERIM PRESIDENT AND CEO 0 Common Stock 2024-04-01 4 M 0 9467 A 1288912 D Common Stock 2024-04-01 4 F 0 3224 1.26 D 1285688 D Restricted Stock Units 2024-04-01 4 M 0 9467 0 D Common Stock 9467 123067 D Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. /s/ Matthew Rothman, Attorney-in-Fact 2024-04-03